


1FW



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	FILING OR 371 (c) DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/815,557	03/31/2004	John F. Engelhardt	875.085US1

CONFIRMATION NO. 7148

FORMALITIES LETTER



OC000000014719498

21186
SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.
P.O. BOX 2938
MINNEAPOLIS, MN 55402

Date Mailed: 12/10/2004

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Filing Date Granted


Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application clearly fails to comply with the requirements of 37 CFR. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- To Download Patent Software, visit <http://www.uspto.gov/web/patents/software.htm>
- For Patent Software Program Help, call (571) 272-2510 or email mark.spencer@uspto.gov

Replies should be mailed to: Mail Stop Missing Parts
Commissioner for Patents
P.O. Box 1450
Alexandria VA 22313-1450



A copy of this notice MUST be returned with the reply.

Meaza.W
Customer Service Center
Initial Patent Examination Division (703) 308-1202
PART 2 - COPY TO BE RETURNED WITH RESPONSE



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: John F. Engelhardt et al.

Title: COMPOUNDS AND METHODS FOR PHARMICO-GENE THERAPY OF
EPITHELIAL SODIUM CHANNEL ASSOCIATED DISORDERS

Docket No.: 875.085US1

Filed: March 31, 2004

Examiner: Unknown

Serial No.: 10/815,557

Due Date: February 10, 2005

Group Art Unit: 1653

Mail Stop Missing Parts
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

We are transmitting herewith the attached:

- ☒ A return postcard.
- ☒ Notice to Comply with Requirements For Patent Applications Containing Sequence Disclosures (3 pgs.).
- ☒ Communication Re: Corrected Application Papers (1 pg.).
- ☒ Sequence Listing (3 pgs).
- ☒ Preliminary Amendment (4 pgs).

Applicant claims small entity status under 37 C.F.R. 1.27.

Please charge any additional required fees or credit overpayment to Deposit Account No. 19-0743.

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.

Customer Number: 21186


By: 

Name: Janet E. Embretson

Reg. No. 39665

JEE:CMG:djk

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Attn: Mail Stop Missing Parts, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 28 day of December, 2004


Name


Signature



PATENT

10/815,557

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: John F. Engelhardt et al.

Examiner: Unknown

Serial No.: 10/815,557

Group Art Unit: 1653

Filed: March 31, 2004

Docket: 875.085US1

Title: COMPOUNDS AND METHODS FOR PHARMICO-GENE THERAPY OF
EPITHELIAL SODIUM CHANNEL ASSOCIATED DISORDERS

COMMUNICATION RE: CORRECTED APPLICATION PAPERS

Mail Stop Missing Parts
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

In response to the "Notice to Comply with Requirements For Patent Applications
Containing Sequence Disclosures" which indicated "Corrected Papers" additionally required,
enclosed is a sequence listing for the above-mentioned application.

Applicants assume the application is now in proper order and in condition for
examination. Please direct any inquiries to the undersigned attorney at (612) 373-6959.

If necessary, please charge any additional fees or credit overpayment to Deposit Account
19-0743.

Respectfully submitted,
John F. Engelhardt et al.

By their Representatives,
SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.
P.O. Box 2938
Minneapolis, MN 55402
(612) 373-6959

Date

December 21, 2004

By

Janet E. Embretson

Reg. No. 39,665

JEE:CMG:djk

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the
United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Attn: Mail Stop Missing
Parts, Commissioner for Patents, P.O.Box 1450, Alexandria, VA 22313-1450, on this 28 day of December, 2004

Dennis J. Knapf

Name

Signature